文献速递血液净化与透析水电解质与酸碱

质子泵抑制剂使用与血液透析患者死亡风险的相关性

Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients.
PubMed 文献 · Kidney Int Rep · 2017-11-10

这项回顾性多中心倾向性评分匹配研究基于EuCliD数据库,评估了血液透析患者使用质子泵抑制剂(PPI)与死亡风险的关系。研究发现PPI使用与低镁血症相关,并且是全因死亡和心血管死亡的独立预测因素;在倾向性评分匹配后,PPI组全因死亡和心血管死亡风险仍较高。结论提示PPI治疗应定期监测并在有指征时使用。

要点

  • PPI使用与血液透析患者低镁血症风险增加相关(OR=2.70)。
  • PPI使用是全因死亡和心血管死亡的独立预测因素。
  • 倾向性评分匹配后,PPI组全因和心血管死亡风险仍较高。

核心结论

  • 研究数据提示血液透析患者使用PPI应定期监测并在有指征时处方。

研究设计与样本

  • 回顾性多中心倾向性评分匹配研究,数据来自EuCliD数据库。
  • 研究纳入1776例接受PPI治疗的血液透析患者与466例未接受PPI治疗的患者,最终匹配成两组各410例患者。

主要发现

  • PPI使用与低镁血症(Mg <1.8 mg/dl(0.75 mmol/l))相关,OR=2.70,95%CI=1.38-5.27,P<0.01。
  • 在全队列中,PPI暴露是全因死亡的独立预测因素,单变量HR=3.16(95%CI=1.69-5.90,P<0.01),多变量HR=2.70(95%CI=1.38-5.27,P<0.01)。
  • PPI使用是心血管死亡的预测因素,HR=1.51(95%CI=1.05-2.20,P=0.03)。
  • 在倾向性评分匹配的820例患者中,PPI组全因死亡风险(HR=1.412,95%CI=1.04-1.93,P=0.03)和心血管死亡风险(HR=1.67,95%CI=1.03-2.71,P=0.04)高于非PPI组。

临床怎么用

  • 对血液透析患者处方PPI时应严格评估指征,避免长期不合理使用。
  • 使用PPI的血液透析患者应定期监测血镁水平及死亡风险相关指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Long-term inappropriate proton pump inhibitors use (PPIs) is a matter of concern because of the risks associated with their long-term use in older patients with chronic conditions. The risk of PPI treatment in hemodialysis patients remains unexplored. METHODS: We assessed the relationship between the use of PPIs and the risk of death in hemodialysis patients throughout a retrospective multicenter propensity score-matched study. Information about demographic, hemodialysis treatment, laboratory data, and concomitant medication was obtained from the EuCliD database (Fresenius Medical Care). We studied 1776 hemodialysis patients on PPI therapy compared to 466 patients not receiving PPIs. The resulting population comprising 2 groups of 410 matched patients was studied. RESULTS: PPI use was associated with hypomagnesemia (Mg <1.8 mg/dl (0.75 mmol/l); odds ratio [OR] = 2.70, 95% confidence interval [CI] = 1.38-5.27, P < 0.01). The exposure to PPIs in the full patient cohort was identified as an independent predictor for all-cause mortality in both univariate (HR = 3.16, 95% CI = 1.69-5.90, P < 0.01) and multivariate (HR = 2.70, 95% CI = 1.38-5.27, P < 0.01) Cox regression models. Moreover PPI use was identified as a predictor of CV mortality (HR = 1.51, 95% CI = 1.05-2.20, P = 0.03) Of the 820 patients matched throughout the propensity score analysis, the hazard ratios for all-cause mortality (HR = 1.412, 95% CI = 1.04-1.93, P = 0.03) and CV mortality (HR = 1.67, 95% CI = 1.03-2.71, P = 0.04) were higher among patients on PPIs versus those not on PPIs. CONCLUSION: The study data suggest that the PPI treatment should be regularly monitored and prescribed only when indicated.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. de Francisco ALM, Varas J, Ramos R, et al. Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients. Kidney Int Rep. 2017. PMID: 29725641. doi:10.1016/j.ekir.2017.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。